ArticleUrology annals
Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients.
Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to present the prevalence of incidental prostate cancer (IPCa) based on pathology reports of prostate tissue chips following transurethral resection of the prostate (TURP), as well as to assess cancer's stage, associated risk factors, and treatment modalities upon diagnosis. Methods: This cross-sectional retrospective study included patients who underwent TURP between 2015 and 2023. Patients with a preexisting PCa diagnosis were excluded, resulting in the analysis of 418 patients. Data collected encompassed basic characteristics, personal history of malignancies unrelated to IPCa, prostate volume, and prostate-specific antigen (PSA) levels. IPCa cases were identified through the pathology reports of the prostatic chips. In addition, cancer stage, Gleason score, treatment choices, and outcomes were documented for IPCa cases. Results: Among the 418 patients who underwent TURP, 35 were diagnosed with IPCa, yielding a prevalence rate of 8.4% (95% confidence interval: 5.7%-11.0%). Of these cases, 13 (37.1%) exhibited metastatic disease, and 4 (11.8%) resulted in patient mortality. IPCa patients were found to have significantly higher PSA levels and smaller prostate volumes. Multivariable logistic regression analysis indicated that elevated PSA density, ischemic heart disease, and chronic kidney disease, significantly influenced the likelihood of IPCa ( Conclusion: Our study disclosed an IPCa prevalence of 8.4%, with IPCa patients exhibiting elevated PSA levels and reduced prostate volumes, suggesting that PSA density is a valuable tool for evaluating patients with borderline PSA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.